Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05566054
Other study ID # SZAMLM5
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 1, 2022
Est. completion date September 30, 2025

Study information

Verified date November 2023
Source The First Affiliated Hospital of Soochow University
Contact Sheng-Li Xue, M. D.
Phone 008651267781139
Email slxue@suda.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy


Description:

Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for patients who are unable to undergo intensive chemotherapy. Venetoclax in combination with hypomethylation agents or cytarabine has been approved by the Food and Drug Administration (FDA) for the treatment of patients with newly diagnosed AML unfit for intensive chemotherapy. However, resistance to venetoclax can be acquired through the upregulation of anti-apoptotic proteins in the BCL2 family, such as myeloid cell leukaemia 1 (MCL1). MCL1 plays a critical role in cell apoptosis regulation and high expression of MCL1 is observed in acute monocytic leukemia (AML-M5) . Chidamide, a newly designed selective histone deacetylase inhibitor, resulted in a decrease in the protein level of MCL1. This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed AML-M5 patients that are ineligible for intensive chemotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 92
Est. completion date September 30, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Confirmation of acute monocytic leukemia( AML-M5) diagnosis by the French-American-British (FAB) Classification and/or characterized for expression of monocytic and myeloid differentiation markers, have a projected life expectancy of at least 12 weeks, previously untreated, and ineligible for treatment with intensive chemotherapy. Patients must be considered ineligible for induction therapy defined by the following: 1. >= 60 years of age 2. >=18 to 59years of age with at least one of the following comorbidities: Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy: (A)Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3. (B)Cardiac history of congestive heart failure requiring treatment or ejection fraction <= 50% or chronic stable angina. (C)Diffusing capacity of the lung for carbon monoxide (DLCO) <= 65% or forced expiratory volume during the first second (FEV1) <= 65%. (D)Creatinine clearance >= 30 mL/min to < 45 mL/min. (E)Moderate hepatic impairment with total bilirubin > 1.5 to <= 3.0 × upper limit of normal (ULN). 3. Must meet the laboratory requirements per the protocol. 4. Female participant must not be pregnant or breastfeeding and is not considering becoming pregnant or donating eggs during the study or for approximately 90 days after the last dose of study drug. 5. Female participants of childbearing potential must agree to use at least 1 protocol-specified method of birth control and male participants, if sexually active with female partner(s) of childbearing potential, must agree to practice the protocol-specified contraception. 6. Did not receive radiotherapy, chemotherapy, targeted therapy or hematopoietic stem cell transplantation within 4 weeks before enrollment; 7. Other comorbidities that are not suitable for intensive chemotherapy; 8. The patient refused to receive intensive chemotherapy; 9. Ability to understand and willing to sign the informed consent for this trial. Exclusion Criteria: 1. Patients who are allergic to the study drug or drugs with similar chemical structures 2. Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception 3. Active infection 4. Active bleeding 5. Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment 6. Patients with mental disorders or other conditions whereby informed consent cannot be obtained and where the requirements of the study treatment and procedures cannot be met 7. Liver function abnormalities (total bilirubin > 1.5 times the upper limit of the normal range, ALT/AST > 2.5 times the upper limit of the normal range or patients with liver involvement whose ALT/AST > 1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine > 1.5 times the upper limit of the normal value) 8. Patients with a history of clinically significant QTc interval prolongation (male > 450 ms; female > 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment 9. Urgery on the main organs within the past six weeks 10. Drug abuse or long-term alcohol abuse that would affect the evaluation results 11. Patients who have received organ transplants (excepting bone marrow transplantation) 12. Patients not suitable for the study according to the investigator's assessment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chidamide
Chidamide 10mg orally daily for 7 days (d1-d7)
Azacitidine
azacytidine 75mg/m2 daily for 7 days (d1-d7)
Venetoclax
Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28)

Locations

Country Name City State
China The First Affliated Hospital of Soochow University Suzhou Jiangsu

Sponsors (8)

Lead Sponsor Collaborator
The First Affiliated Hospital of Soochow University Affiliated Hospital of Nantong University, First Affiliated Hospital Bengbu Medical College, Jining Medical University, Northern Jiangsu Province People's Hospital, Suzhou Hospital of Traditional Chinese Medicine, Taizhou University, The Second People's Hospital of Huai'an

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite Complete Remission Rate The composite complete remission rate(complete remission plus complete remission with incomplete blood cell count recovery) At the end of Cycle 1 or 2 (each cycle is 28 days)
Primary Overall response rate (ORR) The overall response (completed remission without minimal residual disease, completed remission with incomplete blood count recovery, morphologic leukemia-free state and partial remission) At the end of Cycle 1 or 2 (each cycle is 28 days)
Secondary Duration of Response (DOR) It is measured the time from initial response to subsequent disease progression or relapse 1 year
Secondary Overall Survival (OS) It is measured from the time of entry into this trial to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive 1 year
Secondary Progression-Free Survival (PFS) It is measured from the time from randomization to progression or death 1 year
Secondary Adverse reactions in hematology Record of adverse events in hematological system during and after VEN+AZA+Chidamide regimen induction (agranulocytosis days, PLT/RBC transfusion units) At the end of Cycle 1 (each cycle is 28 days)
Secondary Nonhematological adverse reactions Record of adverse events in other organs or systmes during and after VEN+AZA+Chidamide regimen induction (infection and organ injury) At the end of Cycle 1 (each cycle is 28 days)
See also
  Status Clinical Trial Phase
Recruiting NCT05388734 - Shared Decision Making on Care Pathways and CAMs: A Pilot Study N/A
Recruiting NCT03641456 - VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma Phase 2
Completed NCT04554485 - Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL) Phase 2
Not yet recruiting NCT06409702 - Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Active, not recruiting NCT03522246 - A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy Phase 3
Recruiting NCT05833893 - Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma Phase 2
Not yet recruiting NCT05287984 - Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL Phase 2
Not yet recruiting NCT04254640 - Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML Phase 2
Active, not recruiting NCT04216329 - Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Phase 1
Active, not recruiting NCT05284591 - Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)
Completed NCT00632255 - Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment
Recruiting NCT02677064 - Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
Suspended NCT04554459 - Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL Phase 2
Active, not recruiting NCT01844986 - Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. Phase 3
Completed NCT01147627 - Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients N/A